Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient

 

Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient
D

2021 Experimental Therapies for Relapsed Myeloma: Antibodies (Dara, Isa, Elo), ADCs (Blenrep, MEDI2228), Small Molecules (Selinexor, Venetoclax), New Trials (Iberdomide, Melflufen, CPT, TAK-573, Tasquinimod)

By Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient FEATURING Dan Vogl
By Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient FEATURING Dan Vogl
0 views
March 2, 2021
Comments 0
Login to view comments. Click here to Login

Featured Video

23:35
University of Colorado Division of Hematology

2024 Updates in PV/ET

Feat. B. McMahon

Featured Video

24:35
Indy Hematology Review

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Feat. A. Tefferi
Controversies and Update for Patient Care in Multiple Myeloma
17:23
Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient

UPenn Expert Analysis 40 y/o Patient With MM: How to Treat Systemica…

Feat. E. Stadtmauer, D. Vogl, A. Cohen, S. Wallace
10:17
Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient

UPenn Physicians Analyze a Challenging Case of MM: What Systemic The…

Feat. E. Stadtmauer, D. Vogl, A. Cohen, S. Wallace
15:36
Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient

CAR-T and IO for R/R MM in 2021: Is bb2121 Safe and Does It Improve …

Feat. A. Cohen
15:36
Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient

bsAb and IO for R/R MM in 2021: Are Teclistamab, Talquetamab, & …

Feat. A. Cohen
22:31
Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient

2021 Experimental Therapies for Relapsed Myeloma: Antibodies (Dara, …

Feat. D. Vogl